See more : Sime Darby Plantation Berhad (SDPNF) Income Statement Analysis – Financial Results
Complete financial analysis of Pulmatrix, Inc. (PULM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pulmatrix, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- DAEDUCK ELECTRONICS Co., Ltd. (35320K.KS) Income Statement Analysis – Financial Results
- Jet Airways (India) Limited (JETAIRWAYS.BO) Income Statement Analysis – Financial Results
- Dawson Geophysical Company (DWSN) Income Statement Analysis – Financial Results
- The Bank Of Kochi, Ltd. (8416.T) Income Statement Analysis – Financial Results
- MarketEnterprise Co.,Ltd (3135.T) Income Statement Analysis – Financial Results
Pulmatrix, Inc. (PULM)
About Pulmatrix, Inc.
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.30M | 6.07M | 5.17M | 12.63M | 7.91M | 153.00K | 335.00K | 835.00K | 1.20M | 352.00K | 653.00K | 0.00 |
| Cost of Revenue | 15.52M | 1.55M | 15.38M | 0.00 | 12.85M | 12.97M | 10.24M | 10.15M | 7.19M | 6.59M | 8.56M | 0.00 |
| Gross Profit | -8.22M | 4.53M | -10.21M | 12.63M | -4.94M | -12.81M | -9.91M | -9.32M | -5.99M | -6.24M | -7.91M | 0.00 |
| Gross Profit Ratio | -112.63% | 74.55% | -197.58% | 100.00% | -62.39% | -8,374.51% | -2,957.61% | -1,115.81% | -498.42% | -1,772.16% | -1,211.49% | 0.00% |
| Research & Development | 15.52M | 18.24M | 15.38M | 15.61M | 12.85M | 12.97M | 10.24M | 10.15M | 7.19M | 1.38M | 258.00K | 20.00K |
| General & Administrative | 6.52M | 6.78M | 6.38M | 6.89M | 8.49M | 7.52M | 7.57M | 8.02M | 9.63M | 1.74M | 265.00K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.40M | 0.00 | 0.00 | 0.00 |
| SG&A | 6.52M | 6.78M | 6.38M | 6.89M | 8.49M | 7.52M | 7.57M | 8.02M | 17.03M | 1.74M | 265.00K | 0.00 |
| Other Expenses | 0.00 | -198.00K | -11.00K | -239.00K | -205.00K | 22.00K | 0.00 | 7.53M | 0.00 | 0.00 | 0.00 | 10.00K |
| Operating Expenses | 22.04M | 25.02M | 21.76M | 22.50M | 21.33M | 20.48M | 17.81M | 18.17M | 24.22M | 3.12M | 523.00K | 30.00K |
| Cost & Expenses | 22.04M | 25.02M | 21.76M | 22.50M | 21.33M | 20.48M | 17.81M | 18.17M | 24.22M | 3.12M | 523.00K | 30.00K |
| Interest Income | 867.00K | 309.00K | 7.00K | 82.00K | 301.00K | 27.00K | 0.00 | 0.00 | 17.00K | 17.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 186.00K | 643.00K | 881.00K | 953.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.48M | 1.55M | 1.24M | 1.04M | 765.00K | 231.00K | 246.00K | 250.00K | 232.00K | 2.00K | 352.00K | 0.00 |
| EBITDA | -13.27M | -17.40M | -15.35M | -9.86M | -13.24M | -20.15M | -17.17M | -29.67M | -25.21M | -3.12M | -3.12M | -30.00K |
| EBITDA Ratio | -181.76% | -312.09% | -251.75% | 3.72% | -158.82% | -13,122.88% | -5,142.99% | -2,045.75% | -1,897.25% | -885.23% | -80.09% | 0.00% |
| Operating Income | -14.74M | -18.95M | -20.17M | -573.00K | -20.69M | -20.33M | -17.48M | -24.87M | -23.02M | -3.12M | -523.00K | -30.00K |
| Operating Income Ratio | -201.97% | -312.09% | -390.15% | -4.54% | -261.59% | -13,288.24% | -5,216.42% | -2,977.96% | -1,916.57% | -885.80% | -80.09% | 0.00% |
| Total Other Income/Expenses | 619.00K | 111.00K | -4.00K | -9.45M | 96.00K | -232.00K | -581.00K | -5.94M | -3.15M | -17.44M | 5.32M | 0.00 |
| Income Before Tax | -14.12M | -18.84M | -20.17M | -19.31M | -20.60M | -20.56M | -18.06M | -30.80M | -26.17M | -3.12M | -523.00K | -30.00K |
| Income Before Tax Ratio | -193.49% | -310.26% | -390.23% | -152.83% | -260.38% | -13,439.87% | -5,389.85% | -3,688.86% | -2,178.77% | -885.80% | -80.09% | 0.00% |
| Income Tax Expense | 0.00 | -111.00K | 2.33M | 9.21M | -205.00K | 68.00K | -62.00K | -2.96M | 2.20M | -15.07M | -2.60M | 0.00 |
| Net Income | -14.12M | -18.73M | -22.51M | -28.52M | -20.39M | -20.56M | -18.06M | -27.84M | -26.17M | -3.12M | -523.00K | -30.00K |
| Net Income Ratio | -193.49% | -308.43% | -435.38% | -225.70% | -257.79% | -13,439.87% | -5,389.85% | -3,334.49% | -2,178.77% | -885.80% | -80.09% | 0.00% |
| EPS | -3.87 | -5.43 | -8.31 | -19.83 | -24.37 | -99.67 | -186.42 | -375.87 | -646.91 | -765.72 | -130.75 | -0.18 |
| EPS Diluted | -3.87 | -5.43 | -8.31 | -19.83 | -24.37 | -99.67 | -186.42 | -375.87 | -646.91 | -765.72 | -130.75 | -0.18 |
| Weighted Avg Shares Out | 3.65M | 3.45M | 2.71M | 1.44M | 836.70K | 206.32K | 96.86K | 74.08K | 40.45K | 4.07K | 4.00K | 170.00K |
| Weighted Avg Shares Out (Dil) | 3.65M | 3.45M | 2.71M | 1.44M | 836.70K | 206.32K | 96.86K | 74.08K | 40.45K | 4.07K | 4.00K | 170.00K |
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
Pulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Source: https://incomestatements.info
Category: Stock Reports